We hypothesised that because epithelial ovarian cancers containing a germline BRCA1/2 mutation often have a better radiological response to platinum-containing chemotherapy compared to tumours with germline BRCA1/2 wild type, they would also have a better histopathological response to NACT. This evidence concerns the gene BRCA1 and neoplasm.